Report date: Tuesday, July 28, 2026, before market open | Call at 8:30 a.m. ET
Centene's Q1 2026 was a blowout that reset the narrative on margin recovery. The company reported first quarter adjusted diluted EPS of $3.37, exceeding our previous expectations for the period, and used the beat to raise full-year adjusted EPS guidance from ">$3" to ">$3.40." Segment-level detail from that quarter will frame expectations for Q2:
This is arguably the single most important swing factor for Tuesday's report and guidance update. Some context matters here: in July 2025, Centene actually withdrew its full-year guidance after Wakely actuarial data revealed a mismatch between the company's ACA risk pool and the broader market — a shock that hammered the stock and the whole sector at the time. Management spent much of the Q1 2026 call explaining the steps taken since (earlier, more collaborative data-sharing across the industry via Wakely) specifically to avoid a repeat surprise.
Notably, there has been no negative pre-announcement or guidance withdrawal this cycle between the April Q1 report and now — a contrast with last year that the market may read as a tentatively good sign, but investors have not yet seen the actual June Wakely read-through, which CFO Drew Asher flagged as "key to allowing us to further refine this assumption." Watch for: - Confirmation (or not) of the anticipated risk-adjustment receivable and any resulting upward revision to the ~3% Marketplace margin assumption. - Updated full-year Marketplace membership trajectory (ended Q1 at 3.58 million, guided to attrite to "a little over 3 million" by year-end). - Any read-through from CMS's shortened 2027 open enrollment period and lingering program-integrity litigation.
Peer read-across is decidedly mixed here and adds risk to the debate. Molina Healthcare, which reported July 22, saw ACA membership collapse to 283,000 from 655,000 a year earlier and management admitted its 2026 pricing action "underestimated" the effect that enrollment declines would have on its risk pools, prompting further planned Marketplace exits. Elevance also flagged a similarly cautious tone across its book. Centene has far larger Marketplace exposure than Molina, so any incremental negative data points from peers raise the stakes for CNC's own commentary.
Medicaid remains Centene's largest and most closely watched segment (12.4 million members, $23.6B of Q1 premium revenue). Key questions for Tuesday: - Can the company sustain HBR improvement without the flu/weather tailwind that helped Q1? Management explicitly said it would be "disappointed" if underlying performance didn't beat its own 93.7% full-year HBR assumption by 15–20 bps. - Medicaid work requirements are beginning to phase in (Nebraska went live in July), and states are starting to build anticipated acuity shifts into rate-setting. Management has expressed confidence that CMS guidance around mid-year rate retros gives the system flexibility, but this is a genuine 2027 wildcard investors will probe. - Fraud/waste/abuse and network-optimization initiatives (including AI-enabled forecasting and payment-integrity tools) are central to the "net trend" narrative — expect updates on whether these programs are scaling as planned.
Medicare Advantage and the PDP business (now 8.78 million standalone Part D members, the largest such book in the country) outperformed in Q1. The bigger issue is 2027: management expects the direct subsidy to rise materially due to elevated 2025/2026 baseline specialty-pharmacy costs feeding into the CMS risk model with a lag, and the company is engaging with CMS on the "balance" program that succeeds the temporary Bridge program. MA remains on track for breakeven in 2027, aided by a favorable final rate notice and rising D-SNP mix (now 40% of the MA book).
Centene used $1.0 billion of proceeds from selling a participating interest in 2025 Part D risk-share receivables to repurchase $1.0 billion of senior notes, pulling debt-to-capitalization down to 43.2% from 46.5% at year-end 2025. With additional maturities due in December 2027 (~$1.2B) and summer 2028 (~$2.3B), expect questions on refinancing plans and whether continued strong cash generation ($4.4 billion of operating cash flow in Q1) opens the door to buybacks or other capital deployment.
The managed-care group has delivered a volatile earnings season so far: - UnitedHealth delivered a blowout quarter, posting adjusted EPS of $6.38 versus a $4.90 estimate and raising full-year guidance to $19.50–$20.00 (from a prior floor of $18.25), driven by better-than-expected medical cost control — seen by some as evidence that industry-wide cost trend may finally be turning favorable. - Elevance Health beat estimates ($7.45 vs. $6.18 consensus) but the stock still fell more than 12% because the guidance raise was viewed as too modest relative to the beat, with continued softness in its Medicaid book (including plans to exit some Medicaid markets). - Molina beat on adjusted EPS ($1.51 vs. $1.39) and raised guidance, but GAAP profit fell 76% year-over-year as Marketplace weakness offset Medicaid/Medicare stability.
The lesson for Centene: a "beat" alone may not be enough. The market has shown it will punish even solid results if the accompanying guidance raise looks too conservative (Elevance) or if Marketplace commentary disappoints (Molina). Given CNC shares are already up sharply off their spring lows, the bar for a positive reaction looks similarly high — investors will be parsing the magnitude of any guidance raise and, especially, management's language on the Marketplace risk-adjustment receivable.
Centene enters this print with real fundamental momentum — Medicaid margins are recovering, Medicare/PDP are outperforming, and the balance sheet has been meaningfully de-risked — but the stock's outsized rally means expectations are elevated and the market has become less forgiving of "good enough" results across the managed-care group this earnings season. The Marketplace/ACA risk-adjustment call is the single biggest swing factor, both for Centene's own numbers and as a read on an issue that blindsided the company (and the sector) just one year ago. A confirmed, quantifiable risk-adjustment benefit alongside a Medicaid margin build could push guidance meaningfully higher and validate the re-rating; a vaguer or more cautious message — even alongside a Q2 beat — risks an Elevance-style "good number, bad reaction."